TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) earnings date, results and what the price requires

    NYSE · SEC CIK 0000818686 · SEC filings checked Oct 16, 2026

    Next report
    Nov 4, 2026
    Estimated from reporting history (98-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
    Last close
    $41.50
    Polygon.io daily close, Oct 16, 2026. End of day, not live.
    Trailing diluted EPS
    $0.61
    Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025 · P/E 68.0

    Previous results (SEC filings)

    Quarter endedReportedRevenueNet incomeDiluted EPSSource
    Jun 30, 2026Jul 29, 2026$4.14B$-576.0M$-0.49Filing
    Mar 31, 2026Apr 29, 2026$3.98B$369.0M$0.31Filing
    Dec 31, 2025Jan 12, 2026$4.71B$481.0M$0.42Filing
    Sep 30, 2025Nov 5, 2025$4.48B$433.0M$0.37Filing
    Jun 30, 2025Jul 30, 2025$4.18B$282.0M$0.24Filing
    Mar 31, 2025May 7, 2025$3.89B$214.0M$0.18Filing
    Dec 31, 2024Jan 29, 2025$4.23B$-217.0M$-0.19Filing
    Sep 30, 2024Nov 6, 2024$4.33B$-437.0M$-0.39Filing

    What would TEVA PHARMACEUTICAL INDUSTRIES LTD have to report for its valuation to change?

    At $41.50, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 42.2% a year, to $3.55. On that path the next quarter needs diluted EPS near $0.53, against $0.37 in the quarter ended Sep 30, 2025.

    Are you considering buying, or do you already own shares?

    Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.

    ResultOriginalYours
    Required EPS growth / year42.2%42.2%
    EPS needed in final year$3.55$3.55

    Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.

    Prepare for earnings across my investments — $399/month

    Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. TEVA goes in with your buy-or-wait comparison and assumptions preserved.

    Start Desk — $399/month

    Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.